Peringkat dalam Saham
#39567
Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a... Headquartered in Leuven, Belgium, and established in 1991, Oxurion N.V. is a biopharmaceutical firm focused on researching, developing, and bringing to market treatments for various ocular conditions worldwide. Its primary commercialized offering is JETREA, a medication used to address vitreomacular adhesion and vitreomacular traction. The company's development pipeline includes THR-149, a plasma kallikrein inhibitor currently undergoing Phase II clinical trials for diabetic macular edema (DME), and THR-687, an integrin antagonist also in Phase II trials for DME. Oxurion has forged strategic partnerships with Bicycle Therapeutics, INC Research, and Galapagos NV. The organization was formerly known as ThromboGenics NV before officially changing its name to Oxurion NV in September 2018.
Kapitalisasi Pasar
$434.03K
Perubahan (1 hari)
-7.14%
Perubahan (1 tahun)
-89.24%
Perdagangan Oxurion N.V. (OXUR)
Harga OXUR dengan kapitalisasi pasar B
Kapitalisasi pasar dari Oxurion N.V.(OXUR)
Kapitalisasi Pasar: $434.03K
Per August 2026, Oxurion N.V. memiliki kapitalisasi pasar sebesar $434.03K. Ini menjadikan Oxurion N.V. sebagai perusahaan 39567th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Oxurion N.V. dari 2006 hingga 2026
OXUR dibandingkan dengan 5 teratas stocks paling populer
| Harga OXUR |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.470T
|
+1,260,186,454.81%
|
|
|
|
|
$4.467T
|
+1,029,217,230.28%
|
|
|
|
|
$4.174T
|
+961,782,373.59%
|
|
|
|
|
$3.700T
|
+852,501,128.88%
|
|
|
|
|
$2.854T
|
+657,643,093.76%
|
